Cargando…

A retrospective qualitative report of symptoms and safety from transcranial focused ultrasound for neuromodulation in humans

Low intensity transcranial focused ultrasound (LIFU) is a promising method of non-invasive neuromodulation that uses mechanical energy to affect neuronal excitability. LIFU confers high spatial resolution and adjustable focal lengths for precise neuromodulation of discrete regions in the human brain...

Descripción completa

Detalles Bibliográficos
Autores principales: Legon, Wynn, Adams, Sarah, Bansal, Priya, Patel, Parantap D., Hobbs, Landon, Ai, Leo, Mueller, Jerel K., Meekins, Gregg, Gillick, Bernadette T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101402/
https://www.ncbi.nlm.nih.gov/pubmed/32221350
http://dx.doi.org/10.1038/s41598-020-62265-8
_version_ 1783511616245989376
author Legon, Wynn
Adams, Sarah
Bansal, Priya
Patel, Parantap D.
Hobbs, Landon
Ai, Leo
Mueller, Jerel K.
Meekins, Gregg
Gillick, Bernadette T.
author_facet Legon, Wynn
Adams, Sarah
Bansal, Priya
Patel, Parantap D.
Hobbs, Landon
Ai, Leo
Mueller, Jerel K.
Meekins, Gregg
Gillick, Bernadette T.
author_sort Legon, Wynn
collection PubMed
description Low intensity transcranial focused ultrasound (LIFU) is a promising method of non-invasive neuromodulation that uses mechanical energy to affect neuronal excitability. LIFU confers high spatial resolution and adjustable focal lengths for precise neuromodulation of discrete regions in the human brain. Before the full potential of low intensity ultrasound for research and clinical application can be investigated, data on the safety of this technique is indicated. Here, we provide an evaluation of the safety of LIFU for human neuromodulation through participant report and neurological assessment with a comparison of symptomology to other forms of non-invasive brain stimulation. Participants (N = 120) that were enrolled in one of seven human ultrasound neuromodulation studies in one laboratory at the University of Minnesota (2015–2017) were queried to complete a follow-up Participant Report of Symptoms questionnaire assessing their self-reported experience and tolerance to participation in LIFU research (I(sppa) 11.56–17.12 W/cm(2)) and the perceived relation of symptoms to LIFU. A total of 64/120 participant (53%) responded to follow-up requests to complete the Participant Report of Symptoms questionnaire. None of the participants experienced serious adverse effects. From the post-hoc assessment of safety using the questionnaire, 7/64 reported mild to moderate symptoms, that were perceived as ‘possibly’ or ‘probably’ related to participation in LIFU experiments. These reports included neck pain, problems with attention, muscle twitches and anxiety. The most common unrelated symptoms included sleepiness and neck pain. There were initial transient reports of mild neck pain, scalp tingling and headache that were extinguished upon follow-up. No new symptoms were reported upon follow up out to 1 month. The profile and incidence of symptoms looks to be similar to other forms of non-invasive brain stimulation.
format Online
Article
Text
id pubmed-7101402
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-71014022020-03-31 A retrospective qualitative report of symptoms and safety from transcranial focused ultrasound for neuromodulation in humans Legon, Wynn Adams, Sarah Bansal, Priya Patel, Parantap D. Hobbs, Landon Ai, Leo Mueller, Jerel K. Meekins, Gregg Gillick, Bernadette T. Sci Rep Article Low intensity transcranial focused ultrasound (LIFU) is a promising method of non-invasive neuromodulation that uses mechanical energy to affect neuronal excitability. LIFU confers high spatial resolution and adjustable focal lengths for precise neuromodulation of discrete regions in the human brain. Before the full potential of low intensity ultrasound for research and clinical application can be investigated, data on the safety of this technique is indicated. Here, we provide an evaluation of the safety of LIFU for human neuromodulation through participant report and neurological assessment with a comparison of symptomology to other forms of non-invasive brain stimulation. Participants (N = 120) that were enrolled in one of seven human ultrasound neuromodulation studies in one laboratory at the University of Minnesota (2015–2017) were queried to complete a follow-up Participant Report of Symptoms questionnaire assessing their self-reported experience and tolerance to participation in LIFU research (I(sppa) 11.56–17.12 W/cm(2)) and the perceived relation of symptoms to LIFU. A total of 64/120 participant (53%) responded to follow-up requests to complete the Participant Report of Symptoms questionnaire. None of the participants experienced serious adverse effects. From the post-hoc assessment of safety using the questionnaire, 7/64 reported mild to moderate symptoms, that were perceived as ‘possibly’ or ‘probably’ related to participation in LIFU experiments. These reports included neck pain, problems with attention, muscle twitches and anxiety. The most common unrelated symptoms included sleepiness and neck pain. There were initial transient reports of mild neck pain, scalp tingling and headache that were extinguished upon follow-up. No new symptoms were reported upon follow up out to 1 month. The profile and incidence of symptoms looks to be similar to other forms of non-invasive brain stimulation. Nature Publishing Group UK 2020-03-27 /pmc/articles/PMC7101402/ /pubmed/32221350 http://dx.doi.org/10.1038/s41598-020-62265-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Legon, Wynn
Adams, Sarah
Bansal, Priya
Patel, Parantap D.
Hobbs, Landon
Ai, Leo
Mueller, Jerel K.
Meekins, Gregg
Gillick, Bernadette T.
A retrospective qualitative report of symptoms and safety from transcranial focused ultrasound for neuromodulation in humans
title A retrospective qualitative report of symptoms and safety from transcranial focused ultrasound for neuromodulation in humans
title_full A retrospective qualitative report of symptoms and safety from transcranial focused ultrasound for neuromodulation in humans
title_fullStr A retrospective qualitative report of symptoms and safety from transcranial focused ultrasound for neuromodulation in humans
title_full_unstemmed A retrospective qualitative report of symptoms and safety from transcranial focused ultrasound for neuromodulation in humans
title_short A retrospective qualitative report of symptoms and safety from transcranial focused ultrasound for neuromodulation in humans
title_sort retrospective qualitative report of symptoms and safety from transcranial focused ultrasound for neuromodulation in humans
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101402/
https://www.ncbi.nlm.nih.gov/pubmed/32221350
http://dx.doi.org/10.1038/s41598-020-62265-8
work_keys_str_mv AT legonwynn aretrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans
AT adamssarah aretrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans
AT bansalpriya aretrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans
AT patelparantapd aretrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans
AT hobbslandon aretrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans
AT aileo aretrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans
AT muellerjerelk aretrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans
AT meekinsgregg aretrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans
AT gillickbernadettet aretrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans
AT legonwynn retrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans
AT adamssarah retrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans
AT bansalpriya retrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans
AT patelparantapd retrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans
AT hobbslandon retrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans
AT aileo retrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans
AT muellerjerelk retrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans
AT meekinsgregg retrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans
AT gillickbernadettet retrospectivequalitativereportofsymptomsandsafetyfromtranscranialfocusedultrasoundforneuromodulationinhumans